Literature DB >> 28506445

Comparison of Features of Fatal Versus Nonfatal Cardiac Arrest in Patients With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy.

Richa Gupta1, Crystal Tichnell1, Brittney Murray1, Stefania Rizzo2, Anneline Te Riele3, Harikrishna Tandri1, Daniel P Judge1, Gaetano Thiene2, Cristina Basso2, Hugh Calkins1, Cynthia A James4.   

Abstract

Once arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is diagnosed, the incidence of sudden cardiac death (SCD) is rare and prognosis is favorable, highlighting the value of early disease recognition. To inform strategies to diagnose ARVD/C before SCD, we sought to characterize clinical, genetic, and family history features of ARVD/C cases first recognized after SCD or resuscitated SCD (sudden cardiac arrest [SCA]). We identified 66 ARVD/C cases submitted to the Johns Hopkins ARVD/C Registry in whom disease was first recognized after SCD (n = 45) or SCA (n = 21) and compared their clinical, genetic, and demographic features with 352 patients (227 probands) diagnosed with ARVD/C by 2010 Task Force Criteria before any arrest. SCD/SCA cases were 65% men and experienced their arrest at 29.3 ± 13.8 years. Exertion precipitated 72% of arrests. Family history was recognized before arrest in 11 cases (17%), and 24 cases (41%) had reported cardiac symptoms before arrest. The SCD/SCA cohort was disproportionately men (65% SCD/SCA vs 50% living, p = 0.03) and younger at both first reported symptom (27.7 ± 13.5 years SCD/SCA vs 33.0 ± 13.6 years living, p = 0.01) and first sustained ventricular arrhythmia (VA) (29.3 ± 13.8 years SCD/SCA vs 35.6 ± 12.9 years living, p <0.001). In addition, survival from first symptom to VA was significantly shorter in SCD/SCA cases (p <0.001). These results suggest that the natural history of ARVD/C may be accelerated in SCD/SCA cases. In conclusion, although symptoms or family history provide a window of opportunity for diagnosis before death, time to intervene after symptom onset is limited.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28506445     DOI: 10.1016/j.amjcard.2017.03.251

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

Review 1.  Risk Stratification in Arrhythmogenic Right Ventricular Cardiomyopathy.

Authors:  Hugh Calkins; Domenico Corrado; Frank Marcus
Journal:  Circulation       Date:  2017-11-21       Impact factor: 29.690

2.  Development of an algorithm for automatic classification of right ventricle deformation patterns in arrhythmogenic right ventricular cardiomyopathy.

Authors:  Marijn H A Groen; Laurens P Bosman; Arco J Teske; Thomas P Mast; Karim Taha; Frebus J Van Slochteren; Maarten J Cramer; Pieter A Doevendans; René van Es
Journal:  Echocardiography       Date:  2020-05-03       Impact factor: 1.724

3.  Diagnostic and therapeutic strategies for arrhythmogenic right ventricular dysplasia/cardiomyopathy patient.

Authors:  Weijia Wang; Cynthia A James; Hugh Calkins
Journal:  Europace       Date:  2019-01-01       Impact factor: 5.214

Review 4.  Risk Stratification in Arrhythmogenic Right Ventricular Cardiomyopathy.

Authors:  Ryan Wallace; Hugh Calkins
Journal:  Arrhythm Electrophysiol Rev       Date:  2021-04

5.  Facts and Gaps in Exercise Influence on Arrhythmogenic Cardiomyopathy: New Insights From a Meta-Analysis Approach.

Authors:  Julia Martínez-Solé; María Sabater-Molina; Aitana Braza-Boïls; Juan J Santos-Mateo; Pilar Molina; Luis Martínez-Dolz; Juan R Gimeno; Esther Zorio
Journal:  Front Cardiovasc Med       Date:  2021-10-18

6.  Arrhythmogenic Right Ventricular Cardiomyopathy in Pediatric Patients: An Important but Underrecognized Clinical Entity.

Authors:  Anneline S J M Te Riele; Cynthia A James; Hugh Calkins; Adalena Tsatsopoulou
Journal:  Front Pediatr       Date:  2021-12-02       Impact factor: 3.418

7.  Comparing clinical performance of current implantable cardioverter-defibrillator implantation recommendations in arrhythmogenic right ventricular cardiomyopathy.

Authors:  Laurens P Bosman; Claire L Nielsen Gerlach; Julia Cadrin-Tourigny; Gabriela Orgeron; Crystal Tichnell; Brittney Murray; Mimount Bourfiss; Jeroen F van der Heijden; Sing-Chien Yap; Katja Zeppenfeld; Maarten P van den Berg; Arthur A M Wilde; Folkert W Asselbergs; Hariskrishna Tandri; Hugh Calkins; J Peter van Tintelen; Cynthia A James; Anneline S J M Te Riele
Journal:  Europace       Date:  2022-02-02       Impact factor: 5.214

8.  Diagnosing arrhythmogenic right ventricular cardiomyopathy by 2010 Task Force Criteria: clinical performance and simplified practical implementation.

Authors:  Laurens P Bosman; Julia Cadrin-Tourigny; Mimount Bourfiss; Mounes Aliyari Ghasabeh; Apurva Sharma; Crystal Tichnell; Rob W Roudijk; Brittney Murray; Harikrishna Tandri; Paul Khairy; Ihab R Kamel; Stefan L Zimmerman; Johannes B Reitsma; Folkert W Asselbergs; J Peter van Tintelen; Jeroen F van der Heijden; Richard N W Hauer; Hugh Calkins; Cynthia A James; Anneline S J M Te Riele
Journal:  Europace       Date:  2020-05-01       Impact factor: 5.214

9.  [Anesthetic management in a patient with arrhythmogenic right ventricular cardiomyopathy and an implantable cardioverter defibrillator: a case report].

Authors:  Yoko Ohyama; Hiroshi Hoshijima; Jun Shimada
Journal:  Braz J Anesthesiol       Date:  2020-05-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.